Sun Pharma Q3 PAT up 32%

Strong sales in US generic market drive profits for the firm

Sun Pharmaceuticals has reported 32% growth in its net profit at Rs 881 crore for the third quarter ended December 31, 2012, on account of strong sales in the US generic market.

US finished dosage sales stood at $276 million, a growth of 32%.
 
The consolidated net sales stood at Rs 2,852 crore, a growth of 33% over same quarter last year.

Branded generic sales in India grew by 13% at Rs 788 crore over Q3 last year while international formulation sales stood at $73 million, a growth of 31%.